Today: 30 April 2026
Snowflake stock price slips after hours; here’s what Wall Street is watching next
27 February 2026
1 min read

Snowflake stock price slips after hours; here’s what Wall Street is watching next

New York, Feb 26, 2026, 18:26 EST — After-hours

  • Snowflake dropped 1.9% in after-hours trading, wiping out a 2.3% gain from Thursday’s regular session.
  • Fourth-quarter product revenue jumped 30%, while contracted backlog surged.
  • Guidance beat forecasts, yet signaled growth is cooling, with investors zeroing in on AI demand and margins.

Snowflake Inc shares dropped 1.9% after the bell on Thursday, erasing some of their earlier advance as investors digested the company’s outlook alongside new AI-related deals.

These shifts are significant: Snowflake’s consumption-based setup means revenue tracks closely with customer activity. The stock often acts as a real-time indicator of corporate IT budgets—particularly now, as more firms shift workloads into AI projects.

Guidance and backlog now matter just as much as the quarter’s numbers. Investors are looking for clear signs that AI demand is driving genuine platform activity—not just generating hype and test runs.

Snowflake shares ended the session at $173.06, a 2.28% gain. After the bell, they slipped to $169.75. In regular trading, the stock moved between $167.20 and $184.42.

Fourth-quarter revenue hit $1.28 billion, according to a regulatory filing on Wednesday. Product revenue, the line most directly reflecting platform usage, climbed to $1.23 billion. Both figures marked a 30% jump from a year ago. Remaining performance obligations—contracted but unrecognized revenue—surged 42% to $9.77 billion. Net revenue retention clocked in at 125%. “The promise of AI became real,” CEO Sridhar Ramaswamy said. CFO Brian Robins cited 740 net new customers for the quarter. SEC

Snowflake is projecting fiscal 2027 product revenue of $5.66 billion, beating Wall Street’s consensus of $5.50 billion, though it’s guiding for product revenue growth to moderate at 27% for both Q1 and the full year, LSEG data show. CEO Ramaswamy told Reuters that more than 2,500 customers now use the company’s Snowflake Intelligence “agentic” platform—software that acts on users’ behalf—and mentioned Snowflake’s biggest contract yet, valued at over $400 million, but didn’t identify the client. D.A. Davidson’s Gil Luria said, “Investors are skeptical about all software companies right now.” Snowflake also revealed two separate multi-year $200 million deals with OpenAI and Anthropic, and confirmed a $600 million acquisition of app-monitoring platform Observe. Investing.com

The forecast’s slowdown takes the air out of the narrative. Snowflake might post solid results, yet shares could swing sharply—customers could clamp down on usage, or AI-related workloads might drive expenses above projections.

Traders are watching for evidence that these new partnerships actually drive consistent consumption. There’s also the question of whether the Observe integration might end up disrupting sales execution or pressuring margins.

Snowflake’s top brass are set to take the stage at the Morgan Stanley Technology, Media & Telecom Conference on March 3, with their presentation locked in for 4:05 p.m. PT. Investors will be watching for updates on AI demand, margin trends, and news on the Observe deal.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Apple stock slips after the bell as tech cools; Cook teases “big week” of launches
Previous Story

Apple stock slips after the bell as tech cools; Cook teases “big week” of launches

PLS Group (ASX:PLS) share price pulls back after lithium shock from Zimbabwe
Next Story

PLS Group (ASX:PLS) share price pulls back after lithium shock from Zimbabwe

Go toTop